These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
782 related articles for article (PubMed ID: 20151938)
21. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families. Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759 [TBL] [Abstract][Full Text] [Related]
22. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502 [TBL] [Abstract][Full Text] [Related]
23. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA; J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759 [TBL] [Abstract][Full Text] [Related]
24. Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study. Reedy M; Gallion H; Fowler JM; Kryscio R; Smith SA Gynecol Oncol; 2002 May; 85(2):255-9. PubMed ID: 11972384 [TBL] [Abstract][Full Text] [Related]
25. Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation. Suthers GK ANZ J Surg; 2007 May; 77(5):314-9. PubMed ID: 17497966 [TBL] [Abstract][Full Text] [Related]
26. [Clinical and molecular diagnosis of inherited breast-ovarian cancer]. Chompret A J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301 [TBL] [Abstract][Full Text] [Related]
27. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development. Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604 [TBL] [Abstract][Full Text] [Related]
28. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Lalloo F; Varley J; Moran A; Ellis D; O'dair L; Pharoah P; Antoniou A; Hartley R; Shenton A; Seal S; Bulman B; Howell A; Evans DG Eur J Cancer; 2006 May; 42(8):1143-50. PubMed ID: 16644204 [TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123 [TBL] [Abstract][Full Text] [Related]
30. The contribution of founder mutations in BRCA1 to breast cancer in Belarus. Uglanitsa N; Oszurek O; Uglanitsa K; Savonievich E; Lubiński J; Cybulski C; Debniak T; Narod SA; Gronwald J Clin Genet; 2010 Oct; 78(4):377-80. PubMed ID: 20507347 [TBL] [Abstract][Full Text] [Related]
31. [The prevalence of BRCA1 mutations among families at high-risk of breast and ovarian cancer in province of Malopolska between 2004-2009]. Blecharz P; Szatkowski W; Klimek M; Urbański K Przegl Lek; 2009; 66(12):1046-8. PubMed ID: 20514903 [TBL] [Abstract][Full Text] [Related]
32. Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling. Beristain E; Martínez-Bouzas C; Guerra I; Viguera N; Moreno J; Ibañez E; Díez J; Rodríguez F; Mallabiabarrena G; Luján S; Gorostiaga J; De Pablo JL; Mendizabal JL; Tejada MI Breast Cancer Res Treat; 2007 Dec; 106(2):255-62. PubMed ID: 17262179 [TBL] [Abstract][Full Text] [Related]
33. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. Kadouri L; Hubert A; Rotenberg Y; Hamburger T; Sagi M; Nechushtan C; Abeliovich D; Peretz T J Med Genet; 2007 Jul; 44(7):467-71. PubMed ID: 17307836 [TBL] [Abstract][Full Text] [Related]
34. A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Donenberg T; Lunn J; Curling D; Turnquest T; Krill-Jackson E; Royer R; Narod SA; Hurley J Breast Cancer Res Treat; 2011 Jan; 125(2):591-6. PubMed ID: 20838878 [TBL] [Abstract][Full Text] [Related]
35. The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania. Elsakov P; Kurtinaitis J; Petraitis S; Ostapenko V; Razumas M; Razumas T; Meskauskas R; Petrulis K; Luksite A; Lubiński J; Górski B; Narod SA; Gronwald J Clin Genet; 2010 Oct; 78(4):373-6. PubMed ID: 20345474 [TBL] [Abstract][Full Text] [Related]
36. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742 [TBL] [Abstract][Full Text] [Related]
37. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer. Dombernowsky SL; Weischer M; Freiberg JJ; Bojesen SE; Tybjaerg-Hansen A; Nordestgaard BG Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2339-42. PubMed ID: 19661094 [TBL] [Abstract][Full Text] [Related]
38. Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2. Metcalfe KA; Poll A; Llacuachaqui M; Nanda S; Tulman A; Mian N; Sun P; Narod SA Clin Genet; 2010 Nov; 78(5):411-7. PubMed ID: 20653694 [TBL] [Abstract][Full Text] [Related]
39. A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques. Bergman A; Flodin A; Engwall Y; Arkblad EL; Berg K; Einbeigi Z; Martinsson T; Wahlström J; Karlsson P; Nordling M Fam Cancer; 2005; 4(2):89-96. PubMed ID: 15951958 [TBL] [Abstract][Full Text] [Related]
40. Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families. Harvey SL; Milne RL; McLachlan SA; Friedlander ML; Birch KE; Weideman P; ; Goldgar D; Hopper JL; Phillips KA Breast Cancer Res Treat; 2011 Dec; 130(3):1057-61. PubMed ID: 21850394 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]